Abstract
Mycobacteria are intracellular pathogens that invade and reside inside macrophages. There has been a rapid resurgence in infections caused by the genus mycobacteria. Chemotherapy of mycobacterial infections is prolonged, hepatotoxic and very often inadequate in achieving optimal drug concentrations inside the cells. Recent advances in controlled delivery systems for drugs such as liposomes have sparked a renewed interest in their potential application for the treatment of mycobacterial infections. The versatility of liposomes in incorporation of hydrophilic / hydrophobic components, non-toxic nature, biodegradability, biocompatibility and property of sustained release makes them attractive candidates for the delivery of antitubercular drugs. Liposome research in the area of mycobacterial diseases has evolved and matured through several phases; from the laboratory to the clinics. This review, thus focuses on the use of liposomes for the treatment of various types of mycobacterial diseases.
Keywords: liposomes, mycobacterium tuberculosis, mycobacterium avium, drug delivery, chemotherapy, tuberculosis
Current Pharmaceutical Design
Title: Liposome Technology for Drug Delivery Against Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): G. K. Khuller, Manisha Kapur and Sadhna Sharma
Affiliation:
Keywords: liposomes, mycobacterium tuberculosis, mycobacterium avium, drug delivery, chemotherapy, tuberculosis
Abstract: Mycobacteria are intracellular pathogens that invade and reside inside macrophages. There has been a rapid resurgence in infections caused by the genus mycobacteria. Chemotherapy of mycobacterial infections is prolonged, hepatotoxic and very often inadequate in achieving optimal drug concentrations inside the cells. Recent advances in controlled delivery systems for drugs such as liposomes have sparked a renewed interest in their potential application for the treatment of mycobacterial infections. The versatility of liposomes in incorporation of hydrophilic / hydrophobic components, non-toxic nature, biodegradability, biocompatibility and property of sustained release makes them attractive candidates for the delivery of antitubercular drugs. Liposome research in the area of mycobacterial diseases has evolved and matured through several phases; from the laboratory to the clinics. This review, thus focuses on the use of liposomes for the treatment of various types of mycobacterial diseases.
Export Options
About this article
Cite this article as:
Khuller K. G., Kapur Manisha and Sharma Sadhna, Liposome Technology for Drug Delivery Against Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383250
DOI https://dx.doi.org/10.2174/1381612043383250 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Molecular Signaling Pathways as Potential Therapeutic Targets in Osteosarcoma
Current Medicinal Chemistry Screening of Photosynthetic Pigments for Herbicidal Activity with a New Computational Molecular Approach
Combinatorial Chemistry & High Throughput Screening The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Imaging Features of Carcinosarcoma Arising from Adenofibroma of the Uterus: A Case Report
Current Medical Imaging Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry N-Aryl-5-aminopyrazole: A Versatile Architecture in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Mast Cell Disorders In Drug Hypersensitivity
Current Pharmaceutical Design Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials
Current Drug Targets Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) Testicular Cell Junction: A Novel Target for Male Contraception
Current Medicinal Chemistry